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Edited by Ulrike KutayAbstract The EGF-TM7 receptors, a subfamily of adhesion-
GPCRs mostly restricted to leukocytes, are known to express
multiple functional protein isoforms through extensive alterna-
tive cis-splicing. Here, we demonstrate that EGF-TM7
pre-mRNAs also undergo the rare trans-splicing, leading to the
generation of functional chimeric receptors. RT-PCR and in
silico analyses of EMR2 transcripts identiﬁed unique fragments
containing the EGF-like motif 3 of a closely related EGF-TM7
gene, CD97, in addition to the alternative cis-spliced products.
The sequence swapping is restricted to the EGF-3 exon, generat-
ing unique EMR2(1-2-3*-5) and EMR2(1-2-3*-4-5) molecules,
which are functional in ligand-binding as the wild-type
EMR2(1-2-3-4-5) and CD97(1-2-3-4-5) receptors. Our results
suggest that human leukocytes employ trans-splicing as well as
cis-splicing to increase the repertoire of functional adhesion-
GPCRs.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The completion of the human genome project and others has
made it evident that the number of genes in a multi-cellular
organisms genome is far less than previously believed [1,2].
The diversity of the proteome however can be greatly enhanced
from a ﬁxed-size genome through various co-/post-transcrip-
tional and post-translational modiﬁcations. Alternative splic-
ing selectively combines diﬀerent exons of a pre-mRNA to
form diﬀerent mRNA products, which in turn encode proteinAbbreviations: CS, chondroitin sulfate; EGF, epidermal growth factor;
EMR, EGF-like module containing mucin-like hormone receptor;
ERS, exon-recognition sequence; EST, expressed sequence tag; Fc,
fragment crystallisable; GAG, glycosaminoglycans; GPCR, G protein-
coupled receptor; LNB-TM7, class B-related TM7 receptors with a
long N-terminal extracellular domain; TM7, seven-span transmem-
brane
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splicing is thought to be one of the most important co-/post-
transcriptional mechanisms for increasing protein-coding
capacity of the genomes [3–5]. In fact, it has been estimated
that 35–60% of all human genes undergo alternative splicing
[6,7].
Although alternative splicing takes place predominantly in
cis-mode within an individual pre-mRNA, recent studies have
shown that the same splicing reaction can also occur in trans-
mode between separate pre-mRNAs of either the same gene
(intragenic) or diﬀerent genes (intergenic) [5,8]. Thus, intra-
genic trans-splicing could produce mRNAs containing
duplicated exons of one pre-mRNA, whereas intergenic
trans-splicing would be able to join exons of two diﬀerent
pre-mRNAs to form chimeric mRNAs.
Alternative trans-splicing has been identiﬁed in species rang-
ing from unicellular organisms such as trypanosomes to more
complex ones such as Drosophila and mammals [5,8]. In
trypanosomes and Caenorhabditis elegans, trans-splicing is
frequent, but usually involves the joining of a common 5 0
non-coding spliced leader to the downstream polycistronic
genes [9,10]. No protein diversity is generated in this type of
trans-splicing. In Drosophila, trans-splicing is essential for the
functional diversities of mod(mdg4) and lola genes that are
involved in the establishment/maintenance of chromatin struc-
ture and axon guidance pathways, respectively [11–14]. In
mammals, trans-splicing is detected much less frequently. In
addition, it is noted that all mammalian genes known to under-
go trans-splicing also actively engage in cis-splicing [5,8].
Indeed, it was proposed that mammalian trans-splicing might
be a result of splicing noise. Nevertheless, trans-splicing was
clearly demonstrated in both in vitro and in vivo systems
[15–17]. Mammalian trans-splicing has been identiﬁed in
virus-infected cells, which produced combined viral and cellu-
lar RNAs, as well as in several endogenous cellular mRNAs
with duplicated exons [18–22]. Examples of intergenic trans-
splicing between diﬀerent genes have also been reported
elsewhere [23–26]. Recently, RNA trans-splicing has even been
applied as a novel RNA-based gene therapeutic approach to
correct mutant/diseased genes [27,28].
The EGF-TM7 receptors are leukocyte-restricted 7-span
transmembrane (TM7) proteins with multiple extracellular
epidermal growth factor (EGF)-like motifs [29,30]. They
belong to the class of class B-related TM7 receptors with
a long N-terminal extracellular domain (LNB-TM7)blished by Elsevier B.V. All rights reserved.
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GPCR-like molecules having a long extracellular domain
with protein motifs involved in cellular adhesion [31,32]. In
the human genome, a total of 5 EGF-TM7 genes, namely
EMR1,2,3,4, and CD97, are clustered within two regions
on chromosome 19p13 [33]. It is thought that the ancestor
EGF-TM7 gene was created by exon shuﬄing linking the
EGF-like motifs to a secretin receptor-like 7TM gene
[33,34]. From the phylogenetic analysis and the EGF-TM7
gene arrangement on chr.19, it was further suggested that
the EGF-TM7 family was derived from an ancestor gene
through gene duplication and conversion [35]. Thus,
EMR2 was shaped by concerted evolution to be a chimeric
molecule that shares strong homology in the EGF-like
motifs and the 7TM region with CD97 and EMR3, respec-
tively [35].
The EGF-TM7 receptors are characterized by extensive
alternative cis-splicing, resulting in protein isoforms with dif-
ferent numbers of the EGF-like motifs [30,32]. Of note, the
closely related EMR2 and CD97 genes both contain 5 highly
homologous EGF-like motifs that are 97.5% identical [36].
Both genes have been shown to generate mRNA species with
1-2-5, 1-2-3-5, and 1-2-3-4-5 arrangement of the EGF-like
motifs. Another EMR2 isoform was predicted to contain
EGF-like motifs 1-2 only [36–38]. Most importantly, the
resulting protein variants were shown to possess diﬀerent
ligand-binding activities. Thus, the CD55-binding aﬃnity of
CD97 isoforms was found to be in the order of CD97(1-2-
5) > CD97(1-2-3-5) > CD97(1-2-3-4-5), while EMR2(1-2-5)
showed little if any CD55-binding [36,39–41]. In contrast, both
EMR2(1-2-3-4-5) and CD97(1-2-3-4-5), but not other
isoforms, displayed a similar interaction with another cellular
ligand, chondroitin sulfate (CS)-glycosaminoglycans (GAGs)
[42,43]. Alternative splicing therefore provides a means for
the EGF-TM7 receptors to expand their ligand repertoire
and presumably their cellular functions.
In the present study, we provide evidence for alternative
trans-splicing between EMR2 and CD97. We ﬁnd that alter-
native trans-splicing joined speciﬁcally the CD97(EGF-3) exon
between the EGF-2 and EGF-4/EGF-5 exons of EMR2,
creating unique EMR2/CD97(EGF-3) chimeric molecules,
namely EMR2(1-2-3*-5) and EMR2(1-2-3*-4-5) (* denotes
the sequence of CD97 EGF-like motif). We also show that
the chimeric EMR2(1-2-3*-4-5), but not EMR2(1-2-3*-5),
shares similar CS-binding activity with the wild-type
EMR2(1-2-3-4-5) and CD97(1-2-3-4-5). Our data suggest that
human leukocytes use alternative trans-splicing, in addition to
alternative cis-splicing, to further increase the diversity of the
EGF-TM7 receptors.2. Materials and methods
2.1. Reagents and cell culture
General chemicals of analytical grade were obtained from Sigma–
Aldrich (St. Louis, MO, USA), unless otherwise stated. All culture
media were from Invitrogen and were supplemented with 10% heat
inactivated fetal calf serum (FCS), 2 mM L-glutamine, 50 IU/ml peni-
cillin and 50 lg/ml streptomycin. HEK-293T cells, wild-type CHO-K1
and its mutant derivatives (PgsB-618 and PgsD-677) were cultured in
DMEM and Hams F12 medium, respectively. Total RNAs from
pooled human peripheral leukocytes were purchased from BD Biosci-
ences-Clontech.2.2. RT-PCR and DNA analysis
To identify speciﬁc EMR2 transcripts, RT-PCR was performed on
pooled human peripheral leukocytes total RNAs using nested
EMR2-speciﬁc primer sets. In brief, 1 lg of DNA-free total RNAs
were reverse transcribed using random hexamers and MMLV reverse
transcriptase as described previously [36]. The cDNA products
were then ampliﬁed by PCR using the 1st EMR2 primer set: EMR2/
5 0-1,5 0-CTGCTCCTGCCGGCAGCTCAGCTGGAACCAT-3 0 and
EMR2/30-1,50-ACGGGATCCTCCTGCACATCGTAGTGGGCCAT-
GA-30. The resulting RT-PCR products were diluted 200-fold and
re-ampliﬁed again using the 2nd EMR2 primer set: EMR2/50-2,
5 0-AACCATGGGAGGCCGCGTCTTTCTCGTCTTTCTCGCA-3 0
and EMR2/30-2, 5 0-TAGGCCATCCAGCAGGTGACTGGCAC-
ACA-3 0. The ﬁnal products were separated by electrophoresis in 1%
agarose gels. All ampliﬁed DNA fragments were excised from the gel
together in a single gel slice, extracted, and subcloned into the
pCR4-TOPO vector (Invitrogen). A total of 70 random individual col-
onies were selected and sequenced. For Southern blot analysis, PCR
products were digested with or without BamHI prior to gel electropho-
resis. DNA fragments were blotted onto Duralon-UV ﬁlters (Strata-
gene) and hybridized with a EMR2 speciﬁc probe, which was
PCR-ampliﬁed by 5 0-CCTGGGGACCTGGAGACCCTG-3 0 and 5 0-
CAAGGTGACACTCCTGTCTACTT-3 0, representing a DNA frag-
ment at the stalk region. For the search in database of trans-spliced
EMR2 transcripts, the BLAST program was performed using the
EMR2(1-2-3*-4-5) cDNA sequence as a template.2.3. Construction of mFc-fusion expression vectors
EMR2(1-2-3-4-5)-mFc and CD97(1-2-3-4-5)-mFc expression con-
structs have been described previously [43]. The EMR2(1-2-3*-4-5)-
and EMR2(1-2-3*-5)-mFc constructs were generated similarly by
cloning the appropriate PCR-ampliﬁed EGF-like motifs in frame
upstream of the mFc fragment via HindIII and EcoRI sites. The con-
structs were expected to express mFc-fusion proteins containing the
indicated EGF-like motifs and a short stalk region.
2.4. Production of mFc-fusion protein probes
mFc fusion proteins were produced and puriﬁed as described previ-
ously [43]. In brief, 60–70% conﬂuent HEK-293T cells were transfected
with the mFc-fusion expression constructs by calcium phosphate pre-
cipitation method. Typically, 40 lg of plasmid DNA was used for
one T-175 ﬂask of HEK-293T cells. Transfected cells were washed
and fed with fresh OPTI-MEM I medium 16–24 h post-transfection.
Serum-free conditioned media containing the secreted fusion proteins
were collected after 5–6 days of culture, ﬁltered, and passed through
the Protein A-sepharose aﬃnity chromatography column according
the manufacturers protocol (GE Healthcare). After extensive washes,
mFc fusion proteins were eluted from the column with 100 mM glycine
buﬀer, pH 2.9, and immediately neutralized with 1.0 M Tris–HCl, pH
9.0 buﬀer. Puriﬁed proteins were dialyzed in 50 mM Tris–HCl, pH 7.4
buﬀer containing 10 mM CaCl2 and 150 mM NaCl at 4 C. The ﬁnal
protein concentration was measured by the BCA assay (Pierce, Rock-
ford, USA) according to the manufacturers protocol. Puriﬁed proteins
were conﬁrmed by Western blotting, aliquoted, and stored at 80 C
until use.
2.5. Cell-capture assay
To examine the CS-binding ability of the EMR2/CD97 isoforms, a
cell-capture binding assay was performed as described previously
[43,44]. Brieﬂy, the puriﬁed mFc-fusion proteins (5 lg) were coated
onto the pre-washed protein G-conjugated para-magnetic beads
(20 ll) (Protein G Dynabeads, Dynal A.S., Oslo, Norway). The
protein–bead solution was suspended in a ﬁnal volume of 200 ll
PBS/0.1% BSA and mixed thoroughly at room temperature for 1 h.
Following three washes in PBS/0.1% BSA to remove unbound
proteins, the protein–bead complexes were added to wild-type or
mutant CHO-K1 cell lines in a total volume of 0.5 ml at the density
of 1 · 104 cells/ll. The protein–bead-cell mixtures were mixed thor-
oughly by end-over-end rotation at 4 C for 1 h. After extensive
washes and magnetic separation, the captured cells were released
from the beads with PBS/10 mM EDTA at room temperature for
10 min and magnetic separation. Cells were then stained with trypan
blue solution and viable cell numbers were determined by haemocy-
tometer counting.
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3.1. Analysis of EMR2 alternative splicing and identiﬁcation of
trans-spliced EMR2 transcripts
In a previous study examining EMR2 alternative splicing,
we have identiﬁed multiple alternatively cis-spliced transcripts
encoding protein isoforms with EGF-like motifs 1-2, 1-2-5,
1-2-3-5, and 1-2-3-4-5 conﬁgurations [36]. Interestingly, analy-
sis of certain transcripts has unexpectedly yielded non-identical
matches to the wild-type EMR2 cDNA sequences. A more
detailed examination showed that the mismatched region is
localized at the exon encoding the EGF-like motif 3, and when
analyzed further is found to be identical to the highly homol-
ogous 3rd EGF-like motif of CD97 (data not shown).
To conﬁrm the previous observation, we performed a strin-
gent RT-PCR analysis using nested EMR2-speciﬁc primers on
RNA samples isolated from pooled human leukocytes. As
EMR2 and CD97 are highly homologous, we used nested
EMR2-speciﬁc primer sets to minimize the possibility of
non-speciﬁc ampliﬁcation. The primers used here encompass
a region containing the signal peptide, the entire 5 EGF-like
motifs, and a partial stalk region that are unique to EMR2
(see Section 2). As expected, multiple EMR2-speciﬁc cDNA
fragments were identiﬁed (Fig. 1A, lane 1). As controls for pri-
mer speciﬁcity, plasmids containing the full-length EMR2(1-2-
3-4-5) and CD97(1-2-3-4-5) cDNAs were used independently
as templates. As shown in lanes 3 and 4 of Fig. 1A, a speciﬁc1 2MA
B
SP EGF-1 EGF-2EMR2 (1-2-5)
SP EGF-1 EGF-2EMR2 (1-2)
SP EGF-1 EGF-2EMR2 (1-2-3-5)
SP EGF-1 EGF-2EMR2 (1-2-3-4-5)
SP EGF-1 EGF-2EMR2 (1-2-3*-4-5)
SP EGF-1 EGF-2EMR2 (1-2-3*-5)
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Fig. 1. RT-PCR analysis of EMR2 alternative splicing. (A) RT-PCR product
1% agarose gel. Lanes 1 and 2 show the results of RT(+) and RT() temp
1100 bp were detected in the RT(+) sample. The speciﬁcity of the primers us
CD97 and EMR2 cDNA, respectively as templates. (B) The sequence analysis
peptide and stalk region, respectively. The CD97 EGF-3 motif is shown as a g
DNA marker.PCR product was detected only in the reaction containing
EMR2, but not CD97 cDNA template. The multiple speciﬁc
EMR2 cDNA fragments were excised from gels, subcloned,
and a total of 70 independent colonies were sequenced. As
expected, the majority of clones had sequences perfectly
matched to the distinct cis-spliced EMR2 cDNAs (Fig. 1B).
However, a total of 15 out of the 70 clones were found to
contain the sequence of the 3rd EGF-like motif of CD97
(EGF-3*). Speciﬁcally, EMR2(1-2-3*-5) and EMR2(1-2-3*-4-
5) sequences were identiﬁed in 11 and 4 clones, respectively
(Fig. 1B).
The fact that each EGF-like motif of EGF-TM7 proteins is
encoded by an independent single exon [34,36], and that only
the 3rd EGF-like motif but not others were ‘‘swapped’’
between EMR2 and CD97 argue strongly that the RT-PCR
results are genuine. The 7-nucleotide diﬀerence between the
EGF-3 motifs of EMR2 and CD97 further suggests that these
chimeric sequences are not the results of PCR artefact
(Fig. 2A). Finally, as the orientations of EMR2 and CD97
genes on chr.19p13 are in opposite directions, it is unlikely that
the chimeric transcripts are the products of transcrip-
tion-induced gene fusion found in some adjacent genes
[45,46]. Taken together, we conclude that these chimeric tran-
scripts are most likely derived from intergenic alternative
trans-splicing between EMR2 and CD97.
To provide further evidence for the presence of the trans-
spliced transcripts, we took advantage of the BamHI site3 4
STEGF-5 21
ST 3
STEGF-3 EGF-5 14
STEGF-4EGF-3 EGF-5 17
STEGF-4EGF-3 EGF-5 4
STEGF-3 EGF-5 11
Total  70
No. of colonies
s ampliﬁed from RNA of pooled human leukocytes were separated in a
lates, respectively. At least three distinct bands ranging from 800 to
ed in the reaction was conﬁrmed in lanes 3 and 4 using the full-length
of RT-PCR products as seen in (A), lane 1. SP and ST stand for signal
rey box while EMR2 exons are shown as white boxes. M represents the
A
GATGTGGACGAATGTCAGCAGAACCCAAGGCTCTGTAAAAGCTACGGCAC
GATGTGGACGAATGTCAGCAGAACCCAAGGCTCTGTAAAAGCTACGGCAC
CTGCGTCAACACCCTCGGCAGCTACACGTGCCAGTGCCTGCCTGGCTTCA
CTGCGTCAACACCCTTGGCAGCTATACCTGCCAGTGCCTGCCTGGCTTCA
AGCTCAAACCTGAGGACCCGAAGCTCTGCACA
AGTTCATACCTGAGGATCCGAAGGTCTGCACA
EMR2
CD97
EMR2
CD97
EMR2
CD97
B
1 2M
1,000
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500
2,000
1,650
bp
400
300
1 2
C
Fig. 2. Conﬁrmation of trans-spliced EMR2 transcripts. (A) Sequence comparison of the EGF-3 motifs of EMR2 and CD97. The seven diﬀerent
nucleotides between EMR2 and CD97 EGF-3 motifs are highlighted in grey background. The unique BamHI site in CD97 is underlined. The three
potential ERS motifs are indicated by boxes. (B) The RT-PCR products were digested with (lane 1) or without (lane 2) BamHI before gel
electrophoresis. The gel was over-exposed to show the BamHI-digested bands (indicated within a white curly bracket). (C) The same gel was then
analyzed by Southern blotting using a EMR2-speciﬁc probe. The arrows represent BamHI-digested bands that reacted positively to the probe, while
the arrowhead shows non-speciﬁc bands reacting to the probe. M represents the DNA marker.
Table 1
Human EST clones containing trans-spliced EMR2 sequences
Trans-spliced
EGF-like motifs
Accession
number
RNA source
(mRNA length, bp)
1-2-3a DR001061 Human fetal brain (653)
1-2-3a-4 BU507349 Leiomyosarcoma (912)
DA402257 Human thalamus (548)
DA676179 Neutrophils (593)
1-2-3a-4-5 BC082991 Human uterus (3467)
aRepresents the CD97 EGF-like motif.
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(Fig. 2A). RT-PCR products were digested with or without
BamHI, separated by electrophoresis, and hybridized with a
EMR2-speciﬁc probe. Several additional faint but distinct
bands were clearly visible after BamHI digestion (Fig. 2B).
The sizes of the extra bands (380 bp, 430 bp, and
530 bp) correlated nicely to those of the expected BamHI-di-
gested fragments. Furthermore, two of the bands reacted spe-
ciﬁcally to the unique EMR2 3 0-end probe in Southern blotting
analysis (Fig. 2C), indicating an authentic EMR2 sequence.
These results clearly show that there are minor populations
of EMR2-speciﬁc cDNA fragments possessing a unique Bam-
HI site, which is foreign to the wild-type EMR2 sequence.
Taking into the consideration of the previous ﬁndings, it is
believed that these are the trans-spliced EMR2 transcripts con-
taining the CD97 EGF-3* motif.
3.2. In silico analysis of trans-spliced EMR2 transcripts
A survey of human expressed sequence tag (EST) databases
has also identiﬁed examples supporting the presence of trans-
spliced EMR2 transcripts. While 25 EST clones were found
to have perfect sequence matches to various wild-type EMR2
cis-spliced transcripts, a total of 5 EST clones were found to
match, or partly match to the trans-spliced EMR2 transcripts,
but not to the wild-type EMR2 or CD97 sequences (Table 1).
All 5 contain the EGF(1-2-3*) sequence and one especially rep-
resents a full-length EMR2 cDNA with EGF(1-2-3*-4-5)-TM7
conﬁguration (clone BC082991). As these EST clones are of
high quality cDNA sequences derived from diﬀerent tissues
by independent groups, it is reasonable to believe they are the
true representatives of transcripts expressed by these tissues.
With the 3 diﬀerent lines of evidence described above, we
suggest that alternative trans-splicing events indeed occurbetween EMR2 and CD97 pre-mRNAs and potentially lead
to the production of EMR2/CD97 chimeric proteins.
3.3. Functional analysis of the trans-spliced EMR2 transcript
products
We have previously demonstrated that both EMR2(1-2-3-4-
5) and CD97(1-2-3-4-5) interact speciﬁcally with CS-GAG via
the 4th EGF-like motif, whereas other isoforms fail to do so
[42,43]. It is therefore predicted that the trans-spliced EMR2
product EMR2(1-2-3*-4-5), but not EMR2(1-2-3*-5), would
also bind to CS. To test this, a modiﬁed cell-capture binding
assay was performed using a well-established mFc-fusion pro-
tein approach [43,44]. mFc-fusion proteins comprising the
wild-type EMR2(1-2-3-4-5), CD97(1-2-3-4-5), as well as
EMR2(1-2-3*-4-5) and EMR2(1-2-3*-5) were generated inde-
pendently (Fig. 3A), puriﬁed, and coated onto Protein G-con-
jugated Dynabeads. The protein–bead complexes were
subsequently mixed with various CHO-K1 cell lines. Follow-
ing careful washing, bound cells were eluted in EDTA solution
and counted. As predicted, EMR2(1-2-3*-4-5) but not
EMR2(1-2-3*-5) proteins bound to the wild-type CHO-K1
cells and even better to CHO-Pgs677 cells, a mutant CHO cell
Fig. 3. Ligand-binding assay of alternatively spliced EMR2 isoforms. (A) Western blot analysis of puriﬁed mFc fusion proteins. An Fc speciﬁc anti-
mouse IgG-HRP was used to detect the mFc-fusion proteins: mFc alone (lane 1), EMR2(1-2-3-4-5)-mFc (lane 2), EMR2(1-2-3*-5)-mFc (lane 3),
EMR2(1-2-3*-4-5)-mFc (lane 4), CD97(1-2-3-4-5)-mFc (lane 5), and medium control (lane 6). (B) The ligand-binding assay showing the number of
diﬀerent CHO-K1 cell lines captured by the Dynabead complexes containing mFc alone (lane 1), EMR2(1-2-3*-5)-mFc (lane 2), CD97(1-2-3-4-5)-
mFc (lane 3), EMR2(1-2-3-4-5)-mFc (lane 4), or EMR2(1-2-3*-4-5)-mFc (lane 5). The wild-type CHO-K1 cells, PgsB-677, and PgsD-618 mutant cells
analyzed were represented by grey, black, and white bars, respectively. Data shown were means ± S.D. of three independent experiments.
Table 2
The exon–intron organization of EMR2 gene
Exon Exon size (bp) Intron Intron size
(kbp)
EMR2 CD97 EMR2 CD97
1 (5 0-UTR + SP)a P101 P145 1 2.42 6.9
2 (SP) 51 51 2 0.20 0.20
3 (EGF-1) 117 117 3 1.44 2.10
4 (EGF-2) 156 156 4 5.23 5.26
5 (EGF-3) 132 132 5 0.60 0.60
6 (EGF-4) 147 147 6 0.43 0.43
7 (EGF-5) 147 147 7 0.09 0.09
aUTR and SP stand for untranslated region and signal peptide,
respectively.
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a higher level of cell surface CS-GAG (Fig. 3B) [43]. The cell-
binding by EMR2(1-2-3*-4-5) is comparable to the wild-type
EMR2(1-2-3-4-5) and CD97(1-2-3-4-5) probes, consistent with
the previous ﬁnding that the CS-binding activity is mediated
by the 4th EGF-like motif [43]. All probes fail to bind CHO-
Pgs618 cells, another mutant CHO cell line that is deﬁcient
in all types of GAG biosynthesis (Fig. 3B) [43], conﬁrming
the binding speciﬁcity. These results indicate that the products
of the trans-spliced EMR2 transcripts are functional in ligand-
binding. Whether the trans-spliced EMR2 chimeric proteins
are capable of binding to other novel cellular ligand(s) is cur-
rently unknown and is of great interest.
3.4. Potential mechanism and implication of alternative trans-
splicing in the EGF-TM7 protein diversity
Although the molecular mechanisms involved in mediating
and regulating alternative trans-splicing in eukaryotes are
poorly understood, recent studies have slowly unveiled factors
that might be relevant in these processes [5,8]. In addition to
the numerous protein components also employed in cis-splic-
ing, it was reported that certain sequence elements could
potentially promote trans-splicing. These include the purine-
rich exon-recognition sequence (ERS, or exonic-splicing en-
hancer, ESE) in the downstream exon [19,47,48], the 5 0 cryptic
splice sites found in some viral RNAs [15,18], and the presence
of a long intron and/or of an RNA polymerase II pause site
within an intron [49]. As for the regulation of trans-splicing,
nerve growth factor has been shown to up-regulate the trans-
splicing of a voltage-gated sodium channel in rat neurons [21].
A careful examination of the EGF-3 motif of CD97 and
EMR2 has identiﬁed 3 potential purine-rich ERS motifs
(Fig. 2A). Whether they play a role in EMR2/CD97 trans-
splicing will require future study. In addition, we have also
compared the length of the introns in the region containing
the EGF-like motifs. It is interesting to note that in both
EMR2 and CD97 the size of the 4th intron between the
EGF-2 and EGF-3 exons has all exceeded more than 5 kbp
(values are italicized), a much longer sequence in comparison
to other introns (Table 2). Takahara et al. had demonstrated
that delay in the 3 0 splice site synthesis caused by the preceding
intron as short as 4.1 kbp may trigger intragenic trans-splicing[49]. It is tempting to suspect that the long 4th intron might
also contribute to the intergenic trans-splicing of the CD97
EGF-3* motif identiﬁed here.
As EMR2 and CD97 are believed to be duplicated from an
ancestor gene and share strong homology, we wonder whether
the reciprocal trans-splicing event would also occur in CD97,
i.e. CD97 transcripts containing the EGF-like 3 motif of
EMR2. Surprisingly, a search in the EST databases to date
(as of October 2007) has failed to identify any EST clone that
matches to the CD97(1-2-3#-4-5) or CD97(1-2-3#-5) chimeric
transcript (# denotes the sequences of EMR2 EGF-like motif)
(data not shown). This result not only has strengthened the
authenticity of the trans-spliced EMR2 sequences reported
here, but has also further pointed to the unique characteristic
of the EMR2 chimeric transcripts, suggesting an underlying
functional role for the chimeric proteins they translated. The
diﬀerences in the trans-splicing capacity of EMR2 and CD97
genes might provide an opportunity to further dissect the
molecular mechanisms involved. For example, the expression
levels of EMR2 and CD97 in diﬀerent myeloid cell types have
been found to be variable, which might be a factor in promot-
ing trans-splicing [42,50].
In conclusion, we have presented strong evidence that alter-
native trans-splicing occurs between EMR2 and CD97 genes.
The resulting EMR2 chimeric proteins contain a speciﬁc
EGF-like domain (EGF-3) from a closely related gene, CD97,
and are functional in ligand-binding. As well as alternative
P.-L. Chiu et al. / FEBS Letters 582 (2008) 792–798 797cis-splicing, we suggest that trans-splicing is a novel mechanism
for the EGF-TM7 gene family to further expand its protein rep-
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